Caribou Biosciences Inc. (CRBU) Reveals an Earnings Mystery – News Heater
Home  »  Hot Stocks   »  Caribou Biosciences Inc. (CRBU) Reveals an Earning...

Caribou Biosciences Inc. (CRBU) Reveals an Earnings Mystery

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Caribou Biosciences Inc. (NASDAQ:CRBU) went up by 0.45% from its latest closing price compared to the recent 1-year high of $32.65. The company’s stock price has collected -20.54% of loss in the last five trading sessions. Press Release reported on 11/17/21 that Caribou Biosciences to Present at Upcoming Investor Conferences

Is It Worth Investing in Caribou Biosciences Inc. (NASDAQ :CRBU) Right Now?

Opinions of the stock are interesting as 3 analysts out of 3 who provided ratings for Caribou Biosciences Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


The average price from analysts is $30.67, which is $12.99 above the current price. Today, the average trading volume of CRBU was 585.09K shares.

CRBU’s Market Performance

CRBU stocks went down by -20.54% for the week, with a monthly drop of -23.63% and a quarterly performance of -34.59%. The volatility ratio for the week stands at 10.22% while the volatility levels for the past 30 days are set at 7.28% for Caribou Biosciences Inc.. The simple moving average for the period of the last 20 days is -17.76% for CRBU stocks with a simple moving average of -23.45% for the last 200 days.

Analysts’ Opinion of CRBU

Many brokerage firms have already submitted their reports for CRBU stocks, with Citigroup repeating the rating for CRBU by listing it as a “Buy.” The predicted price for CRBU in the upcoming period, according to Citigroup is $27 based on the research report published on November 15th of the current year 2021.

SVB Leerink, on the other hand, stated in their research note that they expect to see CRBU reach a price target of $32. The rating they have provided for CRBU stocks is “Outperform” according to the report published on August 17th, 2021.

Citigroup gave a rating of “Neutral” to CRBU, setting the target price at $27 in the report published on August 17th of the current year.

CRBU Trading at -20.36% from the 50-Day Moving Average

After a stumble in the market that brought CRBU to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.84% of loss for the given period.

Volatility was left at 7.28%, however, over the last 30 days, the volatility rate increased by 10.22%, as shares sank -22.42% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -35.83% lower at present.

During the last 5 trading sessions, CRBU fell by -20.54%, in comparison to the 20-day moving average, which settled at $21.24. In addition, Caribou Biosciences Inc. saw 8.33% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at CRBU starting from MCCLUNG BARBARA G, who purchase 9,219 shares at the price of $2.69 back on Oct 20. After this action, MCCLUNG BARBARA G now owns 342,844 shares of Caribou Biosciences Inc., valued at $24,799 using the latest closing price.

Kanner Steven, the Chief Scientific Officer of Caribou Biosciences Inc., purchase 114,860 shares at $1.92 during a trade that took place back on Oct 12, which means that Kanner Steven is holding 215,031 shares at $220,757 based on the most recent closing price.

Stock Fundamentals for CRBU

Current profitability levels for the company are sitting at:

  • -292.24 for the present operating margin

The net margin for Caribou Biosciences Inc. stands at -277.55. The total capital return value is set at -104.75, while invested capital returns managed to touch -101.51.

>> 7 Top Picks for the Post-Pandemic Economy <<

The receivables turnover for the company is 2.70 and the total asset turnover is 0.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.96.

Sign up for our FREE Newsletter and get:

Leave a Comment

Your email address will not be published. Required fields are marked *

Sign up for our FREE Newsletter and get:

Heading

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

Heading

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam